Koda T, Kurahori T, Iwao N, Sumi S, Sonoda T, Yanagimoto H, Miyaji J, Okahisa N
Gan To Kagaku Ryoho. 1987 Aug;14(8):2571-4.
A patient with gastric cancer (mucinous adenocarcinoma), classified as Borrmann Type 4, refused surgery and a chemotherapy regimen was applied. 5'-DFUR (5'-deoxy-5-fluorouridine) was administered orally at 1,200 mg/day for 23 weeks, for a total dosage of 110.8 g. The patient showed marked remission: the tumor nearly disappeared, distensibility reappeared from the central region of the corpus ventriculi to the incisura angularis, and only small protrusions classified by Yamada's criteria as Type I, remained on the anterior and posterior wall and pars pylorica of the lesser curvature. Side effects were slight anorexia and diarrhea. These could be avoidable by temporal interruption of administration or dosage reduction, to allow long-term treatment. This case can be considered to be one example in which 5'-DFUR proved effective against gastric cancer.
一名被分类为Borrmann 4型的胃癌(黏液腺癌)患者拒绝手术,于是采用了化疗方案。口服5'-DFUR(5'-脱氧-5-氟尿苷),剂量为每日1200毫克,持续23周,总剂量为110.8克。患者显示出明显缓解:肿瘤几乎消失,胃体中部至角切迹处恢复可扩张性,仅在小弯侧前壁、后壁及幽门部残留山田分型为I型的小隆起。副作用为轻度厌食和腹泻。通过暂时中断给药或减少剂量可以避免这些副作用,从而实现长期治疗。该病例可被视为5'-DFUR对胃癌有效的一个实例。